Merck, Schering Offer $42M To Settle Vytorin Suits

By Hilary Russ

Law360, New York (August 05, 2009, 5:16 PM ET) -- Pharmaceutical giants Merck & Co. and Schering-Plough Corp. have said they will pay $41.5 million to settle a host of civil lawsuits over joint marketing and studies of the cholesterol drug Vytorin.

The companies made the announcement Wednesday, saying the deal would settle all class actions — including claims for attorneys' fees, costs and nongovernmental liens — that seek damages related to purchases of the drugs Vytorin and Zetia.

"These agreements will allow the companies to avoid continuing defense costs and remain focused on discovering, developing...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles